Adenocarcinoma, Clear Cell: all 84 studies

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingNCT07718854Phase 2
• Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell CarcinomaRecruitingNCT07072234Phase 1
• Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.Not yet recruitingNCT06574412Phase 2
• A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryRecruitingNCT06279104
• Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of RecurrenceNot yet recruitingNCT06237946
• Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
• A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingNCT06023862Phase 2
• Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 2
• AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
• A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line TherapyRecruitingNCT05460000Phase 2
• Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasRecruitingNCT05415098Phase 1
• An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or BiopsyRecruitingNCT04623502Not applicable
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• A Study of Nivolumab in Selected Uterine Cancer PatientsCompletedNCT03241745Phase 2Results posted
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02315430Phase 2Results posted
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial CancerStatus unknownNCT02065687Phase 2/3Results posted
• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerTerminatedNCT02059265Phase 2Results posted
• A Study of ENMD-2076 in Ovarian Clear Cell CancersCompletedNCT01914510Phase 2Results posted
• Dalantercept in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01642082Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedNCT01307631Phase 2Results posted
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01225887Phase 2Results posted
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT01210222Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01132820Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial CancerCompletedNCT01005329Phase 2Results posted
• Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian CancerCompletedNCT00979992Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial CancerStatus unknownNCT00942357Phase 3Results posted
• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00888615Phase 2Results posted
• Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00888173Phase 2Results posted
• Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00820898Phase 2Results posted
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerStatus unknownNCT00807768Phase 3Results posted
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 3Results posted
• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial CancerStatus unknownNCT00492778Phase 2Results posted
• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial CancerCompletedNCT00416455Phase 1/2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerStatus unknownNCT00108745Phase 3Results posted
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerCompletedNCT00072176Phase 2Results posted
• Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00006011Phase 3Results posted
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedNCT05861778Phase 1
• Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell CarcinomaStatus unknownNCT05759312Phase 1/2
• A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell CarcinomaStatus unknownNCT05600998Not applicable
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• Asian Multicenter Prospective Study of ctDNA SequencingActive, not recruitingNCT05099978
• A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesActive, not recruitingNCT05032040Phase 2
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 1
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell CarcinomaCompletedNCT04735861Phase 2
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
• Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint InhibitorsWithdrawnNCT04680416
• Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable
• Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell AdenocarcinomasStatus unknownNCT03405454Phase 2
• BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2
• A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
• Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumStatus unknownNCT02866370Phase 2
• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaTerminatedNCT02837991Phase 1
• MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
• Ovarian Clear Cell Adenocarcinoma ReviewCompletedNCT02129036
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01935973Phase 1
• Sunitinib® in Patients With Recurrent Ovarian Clear Cell CarcinomaCompletedNCT01824615Phase 2
• Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)WithdrawnNCT01732432
• A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and LymphomasCompletedNCT01625351Phase 1
• Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell CarcinomaActive, not recruitingNCT01582204Not applicable
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving ChemotherapyTerminatedNCT00899093
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus unknownNCT00719303Phase 3
• Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial CancerCompletedNCT00575952Phase 1
• Immunochemotherapy for Metastatic Renal Cell CarcinomaStatus unknownNCT00226798Phase 2
• ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic CancerCompletedNCT00056537Phase 1
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00025467Phase 2
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00005840Phase 1
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00005830Phase 1

← Adenocarcinoma, Clear Cell overview